Poseida Therapeutics PSTX Stock
Poseida Therapeutics Price Chart
Poseida Therapeutics PSTX Financial and Trading Overview
Poseida Therapeutics stock price | 9.5 USD |
Previous Close | 2.41 USD |
Open | 2.37 USD |
Bid | 0 USD x 1300 |
Ask | 0 USD x 1000 |
Day's Range | 2.34 - 2.54 USD |
52 Week Range | 1.95 - 8.82 USD |
Volume | 587.68K USD |
Avg. Volume | 657.39K USD |
Market Cap | 214.34M USD |
Beta (5Y Monthly) | 0.238627 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.4 USD |
PSTX Valuation Measures
Enterprise Value | 55.02M USD |
Trailing P/E | N/A |
Forward P/E | -1.2931937 |
PEG Ratio (5 yr expected) | -0.51 |
Price/Sales (ttm) | 1.5375574 |
Price/Book (mrq) | 1.3601322 |
Enterprise Value/Revenue | 0.395 |
Enterprise Value/EBITDA | -1.479 |
Trading Information
Poseida Therapeutics Stock Price History
Beta (5Y Monthly) | 0.238627 |
52-Week Change | 20.48% |
S&P500 52-Week Change | 20.43% |
52 Week High | 8.82 USD |
52 Week Low | 1.95 USD |
50-Day Moving Average | 2.63 USD |
200-Day Moving Average | 4.38 USD |
PSTX Share Statistics
Avg. Volume (3 month) | 657.39K USD |
Avg. Daily Volume (10-Days) | 621.71K USD |
Shares Outstanding | 86.78M |
Float | 53.42M |
Short Ratio | 8.5 |
% Held by Insiders | 30.50% |
% Held by Institutions | 53.58% |
Shares Short | 4.69M |
Short % of Float | 7.58% |
Short % of Shares Outstanding | 5.40% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -32.13% |
Operating Margin (ttm) | -30.48% |
Gross Margin | -1.93% |
EBITDA Margin | -26.69% |
Management Effectiveness
Return on Assets (ttm) | -9.45% |
Return on Equity (ttm) | -34.28% |
Income Statement
Revenue (ttm) | 139.4M USD |
Revenue Per Share (ttm) | 1.79 USD |
Quarterly Revenue Growth (yoy) | 620.80% |
Gross Profit (ttm) | -22407000 USD |
EBITDA | -37212000 USD |
Net Income Avi to Common (ttm) | -44792000 USD |
Diluted EPS (ttm) | -0.42 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 247.2M USD |
Total Cash Per Share (mrq) | 2.85 USD |
Total Debt (mrq) | 87.89M USD |
Total Debt/Equity (mrq) | 55.78 USD |
Current Ratio (mrq) | 5.354 |
Book Value Per Share (mrq) | 1.816 |
Cash Flow Statement
Operating Cash Flow (ttm) | -13453000 USD |
Levered Free Cash Flow (ttm) | -7568750 USD |
Profile of Poseida Therapeutics
Country | United States |
State | CA |
City | San Diego |
Address | 9390 Towne Centre Drive |
ZIP | 92121 |
Phone | 858 779 3100 |
Website | https://poseida.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 343 |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
Q&A For Poseida Therapeutics Stock
What is a current PSTX stock price?
Poseida Therapeutics PSTX stock price today per share is 9.5 USD.
How to purchase Poseida Therapeutics stock?
You can buy PSTX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Poseida Therapeutics?
The stock symbol or ticker of Poseida Therapeutics is PSTX.
Which industry does the Poseida Therapeutics company belong to?
The Poseida Therapeutics industry is Biotechnology.
How many shares does Poseida Therapeutics have in circulation?
The max supply of Poseida Therapeutics shares is 97.47M.
What is Poseida Therapeutics Price to Earnings Ratio (PE Ratio)?
Poseida Therapeutics PE Ratio is 0.00000000 now.
What was Poseida Therapeutics earnings per share over the trailing 12 months (TTM)?
Poseida Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Poseida Therapeutics company belong to?
The Poseida Therapeutics sector is Healthcare.
Poseida Therapeutics PSTX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
NASDAQ Global Select Market Com NQGS | 8098.63 USD — |
-5.98
|
— — | 8089.65 USD — | 8265.47 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}